HK Stock Market Move | JUNSHI BIO (01877) once rose more than 11% in trading. The outlook for the PD-(L)1/VEGF track has improved.

JUNSHI BIO (01877) once rose more than 11%, it is noteworthy that the stock had previously surged on August 5, with a single-day increase of over 33%. As of the time of writing, it has risen by 8.14% to HK$29.5, with a turnover of HK$531 million. On the news front, JUNSHI BIO completed the placement of 41 million new shares on June 20, raising approximately HK$1.026 billion in net proceeds. The company plans to use 70% of the net proceeds from the placement for the research and development of innovative drugs, such as PD-1/VEGF dual antibodies, EGFR/HER3 ADC, PD-1/IL-2 fusion proteins, and other pipeline developments; and 30% for general corporate purposes including working capital. The founder previously pointed out that JJS207 has BD potential. Overseas pharmaceutical companies are eyeing the huge drug potential of PD1/VEGF, introducing Chinese PD1/VEGF products such as Summit, BioNtech, MSD, Pfizer, and Instil respectively importing the double antibodies PD1 (L1)/VEGF (R) from Kangfang, Pumis, Lixin, Sansheng, and Yiming Oncology. There are still MNCs that have not yet deployed second-generation PD1 products, and JS207 has BD potential. Open Source Securities stated that as of May 2025, only Pfizer and MSD among the MNCs have entered this track through importation, and with the continuous maturation of data and validation of the potential for joint applications, other early-stage Chinese PD-(L)1/VEGF dual antibodies also have the opportunity for BD overseas.